secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001558370-24-009247
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics stockholders elect Clancy and Rossi as Class III directors at annual meeting
--------------------------------------------------------------------------------

- Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors each with ~94.4% of votes cast (excluding broker non-votes).
- Auditor Ernst & Young ratified with 26,199,617 votes for (99.6% of votes cast).
- Broker non-votes of 6,783,293 on director election; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/0001558370-24-009247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/xlo-20240613x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer